Breaking Down SG&A Expenses: Zoetis Inc. vs Bio-Techne Corporation

A Comparative Analysis of SG&A Expenses: Zoetis Inc. vs Bio-Techne Corporation

In the ever-evolving landscape of the pharmaceutical and biotechnology sectors, understanding the financial dynamics of industry leaders is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Zoetis Inc. and Bio-Techne Corporation from 2014 to 2023. Over this period, Zoetis Inc. consistently outpaced Bio-Techne in SG&A spending, with Zoetis peaking at approximately $2.15 billion in 2023, marking a 31% increase from 2014. In contrast, Bio-Techne's SG&A expenses grew by a staggering 554%, reaching nearly $397 million in 2024. This disparity highlights Zoetis's expansive operational scale compared to Bio-Techne's more conservative growth. Notably, the data for Zoetis in 2024 is missing, suggesting a potential shift or anomaly in their financial reporting. Such insights are invaluable for investors and analysts seeking to understand the strategic priorities and operational efficiencies of these industry giants.